Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2007)	7/9/2007 12:36:50 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

BIOM Traded today above its Jul-Jun Hs, but volume remains light. (Nothing like the 5.9M of April 9 & Dec 12.<g>) bigcharts.marketwatch.com The stock is trying to get off from the DT coming from the Apr 9 H at 1.51 bigcharts.marketwatch.com The loss for the 1stQ was cut down some, but revenues were down more than expected. BIOM announced last week that it has submitted an IND to the FDA for PX-478. PX-478 has shown in preclinical studies that it can inhibit HIF-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival. In these preclinical studies, PX-478 produced significant tumor regression and growth delay in multiple models of human cancers, including cancers of the lung, breast, prostate, colon, kidney, pancreas and ovary. Bernard